Related Experiment Video
Updated: May 3, 2026
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
New strategies for triple-negative breast cancer--deciphering the heterogeneity
Ingrid A Mayer1, Vandana G Abramson, Brian D Lehmann
1Authors' Affiliations: Departments of Medicine and Cancer Biology; and Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
Abstract:
Triple-negative breast cancer (TNBC) is a heterogeneous disease; gene expression analyses recently identified six distinct TNBC subtypes, each displaying a unique biology. Exploring novel approaches to treatment of these subtypes is critical because less than 30% of women with metastatic breast cancer survive five years and virtually all women with metastatic TNBC will ultimately die of their disease despite systemic therapy. To date, not a single targeted therapy has been approved for the treatment of TNBC and cytotoxic chemotherapy remains the standard treatment. We discuss the current and upcoming therapeutic strategies being explored in an attempt to "target" TNBC.
Insights
Triple-negative breast cancer (TNBC) is a complex disease with distinct subtypes. Novel targeted therapies are urgently needed as current treatments for metastatic TNBC are largely ineffective.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous malignancy.
- Current treatment options for metastatic TNBC are limited, with poor survival rates.
- The lack of targeted therapies underscores the need for novel treatment strategies.
Purpose of the Study:
- To review current and emerging therapeutic strategies for triple-negative breast cancer.
- To highlight the importance of understanding TNBC subtypes for developing targeted treatments.
- To discuss the challenges and future directions in TNBC therapy.
Main Methods:
- Review of recent gene expression analyses identifying distinct TNBC subtypes.
- Analysis of current clinical trial data for novel TNBC therapeutics.
- Discussion of targeted therapy approaches and their potential impact.
Main Results:
- Gene expression profiling has revealed six distinct subtypes of TNBC.
- No targeted therapies are currently approved for TNBC treatment.
- Cytotoxic chemotherapy remains the standard of care, despite limited efficacy.
Conclusions:
- Understanding TNBC heterogeneity is crucial for developing effective treatments.
- Novel targeted therapies are under investigation to address unmet needs in TNBC.
- Future research should focus on subtype-specific therapeutic strategies for improved patient outcomes.
